title: [Principles and perspectives of primary biliary cirrhosis therapy].
abstract: A survey of existing methods of pathogenetic and symptomatic treatment of primary biliary cirrhosis has been made and it has reviewed prospective directions of its therapy. Is also presents a retrospective analysis of our own data of S-adenosylmethionine (Heptral) in 27 patients PBC receiving UDCA basic therapy. In its application intravenously of 400 mg 2 times daily for 3 weeks showed a reduction in the severity of pruritus, assessed by visual analogue scale, a subjective decrease fatigability and a decrease level of serum bilirubin.
authors: K L
authors: KL
authors: Raĭkhel'son
authors: U A
authors: UA
authors: Mitel'glik
authors: A S
authors: AS
authors: Zubareva
authors: N V
authors: NV
authors: Marchenko
authors: N V
authors: NV
authors: Semenov
authors: A Iu
authors: AIu
authors: Baranovskiĭ
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D012436:S-Adenosylmethionine / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome; D014580:Ursodeoxycholic Acid / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D018160:Receptors, Cytoplasmic and Nuclear; D014580:Ursodeoxycholic Acid; D012436:S-Adenosylmethionine